GKOS vs. HALO, BLCO, OPCH, CRSP, OGN, KRYS, DOCS, BPMC, BBIO, and LNTH
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Halozyme Therapeutics (HALO), Bausch + Lomb (BLCO), Option Care Health (OPCH), CRISPR Therapeutics (CRSP), Organon & Co. (OGN), Krystal Biotech (KRYS), Doximity (DOCS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Lantheus (LNTH). These companies are all part of the "medical" sector.
Halozyme Therapeutics (NASDAQ:HALO) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Halozyme Therapeutics has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a net margin of 33.96% compared to Halozyme Therapeutics' net margin of -42.79%. Glaukos' return on equity of 248.20% beat Halozyme Therapeutics' return on equity.
Halozyme Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Halozyme Therapeutics received 81 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 69.02% of users gave Halozyme Therapeutics an outperform vote while only 64.21% of users gave Glaukos an outperform vote.
In the previous week, Halozyme Therapeutics had 13 more articles in the media than Glaukos. MarketBeat recorded 20 mentions for Halozyme Therapeutics and 7 mentions for Glaukos. Glaukos' average media sentiment score of 1.01 beat Halozyme Therapeutics' score of 0.44 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Halozyme Therapeutics currently has a consensus price target of $53.29, suggesting a potential upside of 38.05%. Glaukos has a consensus price target of $99.80, suggesting a potential upside of 0.47%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Glaukos.
Summary
Halozyme Therapeutics beats Glaukos on 14 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
